IN8bio Phase 1 INB-200 shows mPFS 16.1 months, more than double SOC in GBM

IN8BIO, INC.

Median PFS in repeated-dose patients reached 16.1 months vs 6.9 months historical SOC Stupp protocol.
Four patients (40%) receiving repeated doses remain alive and progression-free for median over two years.
No dose-limiting toxicities, CRS, or ICANS observed; most adverse events Grade 1-2.
Phase 2 INB-400 trial shows preliminary mPFS of 10.8 months; additional data expected late 2025.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.